Table 2.
Summary of CAR-M, CAR-γδT, and CAR-NKT in clinical trials of cancer therapy
| NCT number | Status | Conditions | Target | Phase | Number enrolled | Study start | Study completion |
|---|---|---|---|---|---|---|---|
| CAR-M | |||||||
| NCT04660929 | Recruiting | HER2 overexpressing solid tumors | HER2 | Phase 1 | 48 | 2021, Feb | 2024, Dec |
| NCT05007379 | Not yet recruiting | Breast cancer | HER2 | - | 100 | 2021, Sep | 2023, Sep |
| CAR-γδT | |||||||
| NCT02656147 | Unknown | Leukemia, lymphoma | CD19 | Phase 1 | 48 | 2017, Oct | 2020, Apr |
| NCT04796441 | Unknown | AML | CD19 | Not Applicable | 20 | 2020, Dec | 2022, Feb |
| NCT05554939 | Recruiting | Non-Hodgkin’s lymphoma | CD19 | Phase 1/2 | 30 | 2022.Dec | 2025, Dec |
| NCT04735471 | Recruiting | B cell malignancies | CD20 | Phase 1 | 78 | 2021, Mar | 2024, Mar |
| NCT04911478 | Enrolling by invitation | Lymphoma | CD20 | - | 50 | 2022, Feb | 2039, Aug |
| NCT04702841 | Unknown | Relapsed and refractory CD7 positive T cell-derived malignant tumors | CD7 | Early Phase 1 | 8 | 2020, Jun | 2022, Dec |
| NCT05388305 | Recruiting | AML | CD123 | Not Applicable | 30 | 2022, Apr | 2023, May |
| NCT04107142 | Unknown | Relapsed or refractory solid tumor | NKG2DL | Phase 1 | 10 | 2019, Dec | 2021, Mar |
| NCT05302037 | Not yet recruiting | Advanced cancers | NKG2DL | Phase 1 | 9 | 2022, Apr | 2023, Dec |
| CAR-NKT | |||||||
| NCT03774654 | Recruiting | Relapsed or refractory B cell malignancies | CD19 | Phase 1 | 48 | 2020, Jun | 2035, Mar |
| NCT04814004 | Recruiting | Relapsed/Refractory/High-risk B cell Tumors | CD19 | Phase 1 | 20 | 2021, Mar | 2024, Apr |
| NCT05487651 | Recruiting | B cell malignancies | CD19 | Phase 1 | 36 | 2022, Oct | 2024, Dec |
| NCT02439788 | Withdrawn | Neuroblastoma | GD2 | Phase 1 | 0 | 2017, Aug | 2030, Oct |
| NCT03294954 | Active, not recruiting | Neuroblastoma | GD2 | Phase 1 | 36 | 2018, Jan | 2034, Aug |
Data were obtained from clinicaltrials.gov and updated until July 2023